SYH2092 Injection / Overweight Or Obesity · Phase 1 Trial

A Study of SYH2092 Injection in Healthy Participants

ClinicalTrials.gov · August 20, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a planned Phase 1 trial of SYH2092 Injection, a novel agent being evaluated in the context of overweight or obesity, currently in pre-recruitment status. No efficacy or safety results are available from this registry record. The study aims to establish tolerability and adverse event profile in healthy volunteers over a 71-day period.

What was studied

Phase 1, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Overweight or Obesity; age from 18 Years; to 60 Years; accepts healthy volunteers. Intervention: SYH2092 Injection. Compared with: Placebo — Placebo Comparator. n = 46. 1 site: Australia.

Key findings

Safety

Study has not yet begun recruitment; no results, efficacy data, or safety outcomes are reported in this registry record. Primary outcome is adverse event frequency; no efficacy endpoint or clinical outcome measure is specified.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is an unstarted Phase 1 trial registration with no results posted; it describes planned safety and tolerability assessment in a small healthy population.

Study design

As stated by the source record.

MethodsPrimary outcome measure: Number of participants with treatment-related adverse events as accessed by CTCAE v6.0 (assessed at Screening period up to day 71)

DesignPhase 1, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose

PopulationOverweight or Obesity; age from 18 Years; to 60 Years; accepts healthy volunteers

Sample size46

InterventionSYH2092 Injection

ComparatorPlacebo — Placebo Comparator

Setting1 site: Australia

Reported figures

Quoted from the source exactly as published.

Estimated enrollment46

Study phasePhase 1

Primary outcome measureNumber of participants with treatment-related adverse events as assessed by CTCAE v6.0, Screening period up to day 71

Recruitment statusNOT_YET_RECRUITING

Caveats

Study has not yet begun recruitment; no results, efficacy data, or safety outcomes are reported in this registry record.
Primary outcome is adverse event frequency; no efficacy endpoint or clinical outcome measure is specified.
Eligibility criteria, detailed inclusion/exclusion, and dosing schedule not provided in this registry excerpt.
No information on blinding, allocation concealment, or analysis plan reported.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Phase 1, interventional, placebo-controlled design stated; no results yet posted.

Directness

limited

Safety and tolerability in healthy participants; does not address disease population or clinical outcomes.

Consistency

insufficient

No results reported; consistency cannot be assessed.

Risk of bias

insufficient

Study not yet recruiting; methodology details and blinding approach not fully described.

Sample adequacy

limited

Estimated 46 participants total; appropriate for Phase 1 safety, but small for generalization.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07776041). This is a study registration, not published results. Lead sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 46 participants (ESTIMATED). Conditions: Overweight or Obesity. Interventions: DRUG: SYH2092 Injection; DRUG: Placebo. Primary outcome measures: Number of participants with treatment-related adverse events as accessed by CTCAE v6.0 , Screening period up to day 71. Brief summary: To evaluate the safety and tolerability of SYH2092 Injection in healthy participants

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

SYH2092 InjectionOverweight Or ObesityCSPC Megalith Biopharmaceutical Co.NCT07776041